Finance

TKT Announces Third Quarter Results

Published in Gene Therapy Weekly, December 13th, 2001

Transkaryotic Therapies, Inc., (TKTX) has reported that for the three months ended September 30, 2001, the company had a net loss of $15,868,000, or $0.60 per share, compared with a net loss of $7,506,000, or $0.33 per share, for the corresponding period in 2000.

Replagal (agalsidase alfa) enzyme replacement therapy for Fabry disease received marketing approval in the European Union in August 2001. With the establishment of reimbursement in three countries, the product was launched in late September. During the third quarter of 2001, TKT also continued to record product sales under a compassionate use program, resulting in total sales of $537,000. License and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-12-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry